Overview

The Wanfu combined antibody detection kit for Human Immunodeficiency Virus (HIV) antibody, Hepatitis C Virus (HCV) antibody, Treponema pallidum antibody, and Hepatitis B Virus screening brings four of the most requested serological markers into a single rapid cassette. For B2B buyers serving blood stations, hospitals, physical examination centers, and third-party laboratories, this combination format matches an established screening workflow rather than inventing a new one, which is precisely why it sells steadily across emerging and mature markets.

Why These Four Markers Form One Panel

According to WHO guidance, all blood donations should be screened for HIV, hepatitis B, hepatitis C, and syphilis, and the same four markers are widely used as the standard pre-operative and pre-transfusion screening set in hospitals. Because the four infections share transmission routes and are routinely excluded before surgery, transfusion, pregnancy management, and occupational exposure follow-up, laboratories and clinics test them together as a fixed panel. A four-in-one cassette turns that panel into a single procedure: one sample, one test device, four independently read result positions. For procurement teams, this means simplified stock-keeping compared with four separate products, fewer handling steps for nurses and technicians, and a consistent screening record on one report form.

The Colloidal Gold Method Behind the Kit

The kit follows the immunochromatographic colloidal gold principle that dominates rapid serological testing. A serum, plasma, or whole-blood specimen is applied to the sample well and migrates along a membrane carrying gold-labeled reagents; target antibodies in the specimen are captured at the corresponding test positions, forming visible lines, while a control line verifies that the procedure ran correctly. The assay requires no analyzer, no electricity, and no cold chain during routine use, which makes it practical for county-level hospitals, blood collection points, and field screening programs. As with all rapid antibody screening, reactive results are screening outcomes and must be confirmed using validated laboratory methods according to local clinical practice, a point buyers should keep in any product training material.

Where B2B Demand Comes From

Typical purchasing scenarios include blood stations and plasma collection centers adding rapid backup screening, hospital procurement for emergency and pre-operative departments, physical examination chains bundling the four items into health-check packages, and public-health projects requiring point-of-need testing. When selecting suppliers, buyers commonly confirm the manufacturer's registration documents for each analyte, performance claims with supporting evaluation data, packing specifications, shelf life, and MOQ. Wanfu Biomedical is an established Chinese IVD manufacturer, which supports document completeness and steady supply for bulk programs.

FAQ

Q: Which four markers does this kit combine? A: It combines HIV antibody, HCV antibody, Treponema pallidum antibody, and Hepatitis B Virus screening in one cassette, matching the standard four-item blood-safety panel described in WHO guidance.

Q: Can a reactive line be treated as a final diagnosis? A: No. Rapid antibody tests are screening tools; reactive specimens must be re-tested and confirmed with validated laboratory methods following local clinical guidelines.

Q: Which customer types order this format most often? A: Blood stations, hospital pre-operative and emergency departments, physical examination chains, and public-health screening programs that need one-sample, four-marker workflows.